Abstract 396P
Background
Despite the many cervical cancer prevention interventions recommended and supported by WHO and partners of low- and middle-income countries; the burden of cancer is high in Uganda and the East African region. Little is known about factors associated with participating in screening at a primary health facility (PHF) and referral to a high-level facility.
Methods
A cross-sectional study was conducted from February to March 2018 at Uganda Cancer Institute (UCI) among women visiting for cervical cancer screening. A structured questionnaire was used. Women suspected for cervical cancer and provided consent were enrolled and administered the questionnaire. Ethics review and approval was obtained from UCI research and ethics committee. A Stata version 14.1 software was used and Chi-square tests and multivariate logistic regression analyses performed.
Results
Among 522 women enrolled, only 3.26% (17) had a formal referral note and 62.64% (327) had participated in cervical cancer screening before visiting UCI. There was a 17.65% false-positive rate among the referred women suspected with cervical cancer. 67.18% (131) among those who had never screened reported personal beliefs as a factor deterring their participation. Most women were aged between 35-44 years old (ORs=2.45, 95% CI = 1.61-3.72) who were divorced/widowed (ORs=1.89, 95% CI = 1.07-3.34) and drinking alcohol (ORs=0.51, 95% CI = 0.31-0.83). Among the referred women, 17.65% delayed to honour a referral request for more than a month because of socio-economic challenges. Factors such as high education level (ORs=0.11, 95% CI = 0.02-0.48) and confirmatory tests (ORs=6.10, 95% CI = 1.93-19.31) done at UCI were associated with referrals.
Conclusions
The present study identified factors associated with participation in screening at a PHF and referral to a high-level facility, which provides better understanding of lost follow-up after screening. Awareness in high risk groups, increase of screening facilities and integration of screening services with existing health programs is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Uganda Cancer Institute-African Development Bank capacity building fund.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract